Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 4:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 481 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: SLE (Systemic Lupus) Clear all
Completed No phase listed Observational

Pilot Study to Assess Flares Following Inactivated Influenza Vaccine in Children With Systemic Lupus Erythematosus (SLE)

NCT02006784
View directory record Official record
Conditions
Systemic Lupus Erythematosus (SLE)
Interventions
Not listed
Lead sponsor
Vanderbilt University
Other
Eligibility
8 Years to 18 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 2, 2017 · Synced Sep 11, 2026, 4:14 PM EDT
Recruiting Phase 1 Interventional

Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants

NCT07201558
View directory record Official record
Conditions
Rheumatoid Arthritis, Systemic Lupus Erythematosus
Interventions
Surovatamig
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
5
States / cities
Birmingham, Alabama • Fullerton, California • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 11, 2026, 4:14 PM EDT
Completed Phase 1 Interventional

Monoclonal Antibody Treatment for Systemic Lupus Erythematosus

NCT00046774
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
MRA 003 US
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Sep 11, 2026, 4:14 PM EDT
Not listed Not applicable Interventional

Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases

NCT00006055
View directory record Official record
Conditions
Purpura, Schoenlein-Henoch, Graft Versus Host Disease, Anemia, Hemolytic, Autoimmune, Rheumatoid Arthritis, Churg-Strauss Syndrome, Hypersensitivity Vasculitis, Wegener's Granulomatosis, Systemic Lupus Erythematosus, Giant Cell Arteritis, Pure Red Cell Aplasia, Juvenile Rheumatoid Arthritis, Polyarteritis Nodosa, Autoimmune Thrombocytopenic Purpura, Takayasu Arteritis
Interventions
anti-thymocyte globulin, cyclophosphamide, cyclosporine, filgrastim, methylprednisolone, prednisone, Autologous Peripheral Blood Stem Cell Transplantation
Drug · Procedure
Lead sponsor
Fairview University Medical Center
Other
Eligibility
1 Year to 55 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 11, 2026, 4:14 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Duke Autoimmunity in Pregnancy Registry

NCT00513591
View directory record Official record
Conditions
Pregnancy, Systemic Lupus Erythematosus, Cutaneous Lupus, Rheumatoid Arthritis, Sjogren's Syndrome, Scleroderma
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
513 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 22, 2019 · Synced Sep 11, 2026, 4:14 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

NCT06617325
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
DZP, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
16 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
62
States / cities
Avondale, Arizona • Chandler, Arizona • Gilbert, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 11, 2026, 4:14 PM EDT
Completed No phase listed Observational

Insulin Resistance and Atherosclerosis in Women With Lupus

NCT00544102
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Insulin Resistance, Atherosclerosis
Interventions
Not listed
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
30 Years to 55 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Sep 11, 2026, 4:14 PM EDT
Active, not recruiting Phase 1 Interventional

CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101

NCT06152172
View directory record Official record
Conditions
Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis, SLE Nephritis, ANCA Associated Vasculitis
Interventions
KYV-101, Cyclophosphamide, Fludarabine
Drug
Lead sponsor
David Porter
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Sep 11, 2026, 4:14 PM EDT
Completed Phase 1 Interventional

A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Years Old

NCT06064929
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Felzartamab
Drug
Lead sponsor
HI-Bio, A Biogen Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
14
States / cities
La Jolla, California • San Francisco, California • Stanford, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 11, 2026, 4:14 PM EDT
Completed Phase 2 Interventional Results available

ALPN-101 (Acazicolcept) in Systemic Lupus Erythematosus

NCT04835441
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
ALPN-101, Placebo
Drug
Lead sponsor
Alpine Immune Sciences Inc, A Subsidiary of Vertex
Industry
Eligibility
18 Years to 70 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
29
States / cities
Anniston, Alabama • Phoenix, Arizona • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Sep 11, 2026, 4:14 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus

NCT02446899
View directory record Official record
Conditions
Active Systemic Lupus Erythematosus
Interventions
Anifrolumab, Placebo
Biological · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
373 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
35
States / cities
Covina, California • Hemet, California • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2023 · Synced Sep 11, 2026, 4:14 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants

NCT06576271
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
GSK4527363, Placebo matching GSK4527363, Belimumab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
142 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
6
States / cities
Scottsdale, Arizona • Aurora, Colorado • Las Vegas, Nevada + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Sep 11, 2026, 4:14 PM EDT
Recruiting Phase 4 Interventional

Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users

NCT06594068
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Anifrolumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 11, 2026, 4:14 PM EDT
Completed Phase 2 Interventional Results available

Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis

NCT00774852
View directory record Official record
Conditions
Lupus Nephritis, Lupus Erythematosus, Systemic
Interventions
abatacept, cyclophosphamide, azathioprine, prednisone, abatacept placebo, azathioprine placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
21
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2016 · Synced Sep 11, 2026, 4:14 PM EDT
Recruiting Phase 1 Interventional

A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus

NCT06613360
View directory record Official record
Conditions
SLE, SLE (Systemic Lupus)
Interventions
CLN-978
Drug
Lead sponsor
Cullinan Therapeutics Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
10
States / cities
Avondale, Arizona • Tucson, Arizona • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 11, 2026, 4:14 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Research Registry for Neonatal Lupus

NCT00074373
View directory record Official record
Conditions
Neonatal Lupus, Systemic Lupus Erythematosus, Sjogren's Syndrome, Congenital Heart Block
Interventions
No intervention; observational
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 2, 2023 · Synced Sep 11, 2026, 4:14 PM EDT
Recruiting Phase 1Phase 2 Interventional

Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor

NCT05508009
View directory record Official record
Conditions
SIOD, Cystinosis, FSGS, SLE Nephritis, CKD Stage 4
Interventions
Cyclophosphamide 1200 mg/Kg, Fludarabine, Cyclophosphamide 100 mg/Kg, Total Body Irradiation, ATG, Rituximab, Melphalan, CliniMACS® TCR α/β Reagent Kit and CliniMACS® CD19 System, Kidney Transplant
Drug · Radiation · Device + 1 more
Lead sponsor
Alice Bertaina
Other
Eligibility
1 Year to 30 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2034
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2023 · Synced Sep 11, 2026, 4:14 PM EDT
Terminated Phase 1 Interventional

Nonmyeloablative Allo Stem Cell Transplant for Severe Autoimmune Diseases

NCT00849745
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Systemic Sclerosis
Interventions
Nonmyeloablative allogeneic stem cell transplant
Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years to 69 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 22, 2016 · Synced Sep 11, 2026, 4:14 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Ultraviolet Light Therapy for Systemic Lupus Erythematosus

NCT00004375
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
ultraviolet A-1 light treatment
Procedure
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
15 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1991
U.S. locations
2
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 11, 2026, 4:14 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

The Effect of Milnacipran on Fatigue and Quality of Life in Lupus Patients

NCT01359826
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Widespread Pain, Fibromyalgia
Interventions
Milnacipran
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2015 · Synced Sep 11, 2026, 4:14 PM EDT
Terminated Phase 2 Interventional Results available

Nelfinavir in Systemic Lupus Erythematosus

NCT02066311
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Nelfinavir
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
8
States / cities
Los Angeles, California • Chicago, Illinois • Manhasset, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2020 · Synced Sep 11, 2026, 4:14 PM EDT
Terminated Phase 2 Interventional

Effect of Curcumin on Systemic Lupus Erythematosus

NCT03953261
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Curcumin supplement
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2022 · Synced Sep 11, 2026, 4:14 PM EDT
Recruiting Phase 1 Interventional

Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis

NCT06975787
View directory record Official record
Conditions
Lupus Nephritis (LN)
Interventions
Vonsetamig, Odronextamab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Rochester, Minnesota • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 11, 2026, 4:14 PM EDT
Recruiting Not applicable Interventional

Helping Lupus Patients Manage Fibromyalgia Symptoms Through Emotional Awareness and Expression Therapy (EAET)

NCT07282392
View directory record Official record
Conditions
Lupus, Fibromyalgia (FM), Chronic Widespread Pain
Interventions
Emotional Awareness and Expression Therapy (EAET)
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 28, 2025 · Synced Sep 11, 2026, 4:14 PM EDT